CRISPR Therapeutics AG
CRISPR Therapeutics AG, a pioneering biotechnology company headquartered in Switzerland (CH), is at the forefront of gene editing innovation. Founded in 2013, the company focuses on developing transformative therapies using its proprietary CRISPR/Cas9 technology, which allows for precise modifications to DNA. With a strong presence in Europe and North America, CRISPR Therapeutics is dedicated to addressing serious diseases, particularly in the fields of oncology, regenerative medicine, and genetic disorders. Its lead product candidates, including CTX001 for sickle cell disease and beta-thalassemia, exemplify the unique potential of CRISPR technology to provide curative solutions. Recognised for its significant contributions to the industry, CRISPR Therapeutics AG continues to solidify its market position through strategic partnerships and groundbreaking research, making it a key player in the rapidly evolving landscape of gene editing therapies.
DitchCarbon Score
How does CRISPR Therapeutics AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CRISPR Therapeutics AG's score of 21 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
CRISPR Therapeutics AG's reported carbon emissions
As of the latest available data, CRISPR Therapeutics AG has reported greenhouse gas emissions from the life sciences sector, with specific figures indicating a gradual reduction over the years. In 2012, emissions were approximately 1,880,000 kg CO2e, decreasing to about 1,720,000 kg CO2e by 2014, and further down to around 1,540,000 kg CO2e in 2016. This trend reflects a commitment to reducing carbon emissions, although specific reduction targets or initiatives have not been disclosed. The emissions data does not specify the scopes (Scope 1, 2, or 3) of these emissions, which limits the understanding of the full impact of their operations. Additionally, there are no documented climate pledges or science-based targets (SBTi) that outline their future commitments to carbon reduction. Overall, while CRISPR Therapeutics AG has shown a positive trend in reducing emissions over the years, further transparency regarding their climate commitments and specific reduction strategies would enhance their sustainability profile.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
CRISPR Therapeutics AG is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
